-
公开(公告)号：WO2017165299A2
公开(公告)日：2017-09-28
申请号：PCT/US2017/023216
申请日：2017-03-20
Applicant: AILERON THERAPEUTICS, INC.
Inventor： AIVADO, Manuel
Abstract: The present invention provides diagnostic tools, systems, and methods for detecting wild type p53 and p53-associated mutations for the treatment of disease with peptidomimetic macrocycles.
Abstract translation: 本发明提供了用于检测用拟肽大环化合物治疗疾病的野生型p53和p53相关突变的诊断工具，系统和方法。
-
公开(公告)号：WO2017117381A1
公开(公告)日：2017-07-06
申请号：PCT/US2016/069185
申请日：2016-12-29
Applicant: DUNCAN, Scott
Inventor： DUNCAN, Scott
CPC classification number: C07K5/1019 , A61K38/00
Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of ischemia and ischemia-reperfusion injury comprising administration of at least one peptide disclosed herein, or a pharmaceutically acceptable salt thereof.
Abstract translation: 本文公开了用于治疗和/或预防局部缺血和局部缺血 - 再灌注损伤的方法和组合物，其包括施用本文公开的至少一种肽或其药学上可接受的盐。
-
93.发明申请
公开(公告)号：WO2017102906A1
公开(公告)日：2017-06-22
申请号：PCT/EP2016/081117
申请日：2016-12-15
Applicant: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Inventor： URBAN, Stephan , NI, Yi , MIER, Walter
CPC classification number: A61K51/088 , A61K38/00 , A61K49/0056 , C07K7/06 , C07K7/08 , C07K7/50 , C07K7/64 , C07K14/005 , C12N2730/10111 , C12N2730/10141 , Y02A50/409 , Y02A50/411 , Y02A50/423 , Y02A50/463
Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.
Abstract translation: 本发明涉及作为乙型肝炎病毒（HBV）的preS衍生肽的环状NTCP靶向肽。 本发明进一步涉及包含至少一种环肽的药物组合物。 本发明进一步涉及所述环肽和药物组合物的医疗用途，例如用于诊断，预防和/或治疗肝脏疾病或病症，和/或用于抑制HBV和/或HDV感染。 本发明还涉及诊断，预防和/或治疗肝脏疾病或病症和/或抑制HBV和/或HDV感染的方法。
-
94.发明申请PHARMACEUTICAL ASSOCIATION COMPRISING A GROWTH FACTOR RECEPTOR AGONIST CONJUGATED TO A BIOACTIVE CARRIER FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF 审中-公开包含结合至生物活性载体的生长因子受体激动剂以将嗜碱性细胞转化为非嗜碱性细胞的药物组合物及其用途
公开(公告)号：WO2017046215A3
公开(公告)日：2017-06-22
申请号：PCT/EP2016071781
申请日：2016-09-15
Applicant: HISTIDE AG
Inventor： ZOUANI OMAR F , GOCHEVA VERONIKA
IPC: A61K38/18 , A61K9/16 , A61K38/05 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , A61L27/12 , A61L27/34 , A61L27/54 , A61P35/00 , G06F19/16
CPC classification number: A61K38/18 , A61K38/05 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/1875 , A61K47/50 , A61L27/12 , A61L27/22 , A61L27/24 , A61L27/34 , A61L27/40 , A61L27/54 , A61L2300/416 , A61L2400/06 , A61L2430/02
Abstract: The present disclosure provides a pharmaceutical association for use in the treatment, prevention and/or diagnostic of a neoplastic disease, said association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one bioactive carrier forming at least one covalent or non-covalent interaction with said at least one growth factor receptor-binding compound, and wherein said association reduces or suppresses, in the neoplastic cell, the gene expression of at least one cyclin D and/or reduces or suppresses the formation of at least one complex formed between said at least one cyclin D and at least one of cyclin dependent-kinase 4 or 6.
Abstract translation: 本公开提供了用于治疗，预防和/或诊断赘生性疾病的药物协会，所述协会包含至少一种生长因子受体结合化合物，其激活赘生性细胞的至少一种生长因子受体，以及 至少一种生物活性载体，其与所述至少一种生长因子受体结合化合物形成至少一种共价或非共价相互作用，并且其中所述缔合减少或抑制赘生性细胞中至少一种细胞周期蛋白D的基因表达，和 /或减少或抑制所述至少一种细胞周期蛋白D与细胞周期蛋白依赖性激酶4或6中的至少一种之间形成的至少一种复合物的形成。
-
95.发明申请INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS 审中-公开细菌RNA聚合酶抑制剂：ARYLPROPANOYL，ARYLPROPENOYL和ARYLCYCLOPOPAROPARBOXYL PHLOGOGLUCINOLS
公开(公告)号：WO2017100645A3
公开(公告)日：2017-06-15
申请号：PCT/US2016/065931
申请日：2016-12-09
Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY , EBRIGHT, Richard H. , FREUNDLICH, Joel , MITTAL, Nisha , JASKOWSKI, Mark , SHEN, Juan
Inventor： EBRIGHT, Richard H. , FREUNDLICH, Joel , MITTAL, Nisha , JASKOWSKI, Mark , SHEN, Juan
Abstract: The invention provides compounds that are inhibitors of bacterial RNA polymerase. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
Abstract translation: 本发明提供了作为细菌RNA聚合酶抑制剂的化合物。 本发明还提供包含此类化合物的组合物，制备此类化合物的方法以及使用所述化合物的方法。 本发明可用于控制细菌基因表达，控制细菌生长，抗菌化学和抗菌疗法。
-
Patent Agency Ranking96.发明申请ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННО-ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ МЕСТНОГО ПРИМЕНЕНИЯ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ (ВАРИАНТЫ) 审中-公开用于治疗感染性和炎性疾病的局部应用AND METHOD FOR及其制备和用途的药物组合物（变体）
公开(公告)号：WO2017095266A1
公开(公告)日：2017-06-08
申请号：PCT/RU2016/000815
申请日：2016-11-24
Abstract: Изобретение относится к области медицины и химико-фармацевтической промышленности. Предложена фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний в виде раствора для местного применения, характеризующаяся тем, что она содержит в качестве активного начала комбинацию Грамицидина С дигидрохлорида и цетилпиридиния хлорида, в качестве вспомогательных веществ - этанол 96%, сукралозу, глицерол, лимонную кислоту моногидрат, натрия цитрат, полисорбат, метилпарабен, пропилпарабен, ароматизатор натуральный мятный, воду очищенную. Также предложен способ ее получения и применения.
Abstract translation: 本发明涉及医学和化学和制药工业领域。 用于在局部用溶液的形式治疗感染和炎症性疾病的药物组合物，其特征在于它含有作为活性成分的赋形剂的短杆菌肽小号二盐酸盐和西吡氯铵的组合 - 乙醇96％三氯半乳蔗糖，甘油，柠檬酸一水合物 ，柠檬酸钠，聚山梨酸酯，对羟基苯甲酸甲酯，对羟基苯甲酸丙酯，天然薄荷香料，精制水。 还提出了一种生产和使用的方法。
-
公开(公告)号：WO2017032855A3
公开(公告)日：2017-06-01
申请号：PCT/EP2016070132
申请日：2016-08-25
Applicant: HISTIDE AG
Inventor： ZOUANI OMAR F
Abstract: The present disclosure provides a cyclic peptide, or a variant or analog thereof, or a cyclic peptidomimetic, with between 15 and 35 amino acids, having a growth factor receptor-binding capability and comprising a peptide with four amino acids PEP1, and a peptide with five amino acids PEP2; wherein PEP1 is selected from the group consisting of SAIS, SSLS, NAIS, SATS, SPIS, EPIS, SPIN, KPLS, EPLP, EPLT, SNIT, RSVK and RPVQ; and wherein PEP2 is selected from the group consisting of LKNYQ, LKVYP, LKKYR, LRKHR, LKYHY, KFKYE, YGKIP, YKQYE, DHHKD, EQLSN, IGEMS, LGEMS, KEVQV and KKATV.
Abstract translation: 本公开提供具有15-35个氨基酸的具有生长因子受体结合能力并且包含具有四个氨基酸PEP1的肽的环肽或其变体或类似物或环拟肽，和具有 五种氨基酸PEP2; 其中PEP1选自由SAIS，SSLS，NAIS，SATS，SPIS，EPIS，SPIN，KPLS，EPLP，EPLT，SNIT，RSVK和RPVQ组成的组; 并且其中PEP2选自由LKNYQ，LKVYP，LKKYR，LRKHR，LKYHY，KFKYE，YGKIP，YKQYE，DHHKD，EQLSN，IGEMS，LGEMS，KEVQV和KKATV组成的组。
-
98.发明申请USE OF LYSIN TO RESTORE/AUGMENT ANTIBACTERIAL ACTIVITY IN THE PRESENCE OF PULMONARY SURFACTANT OF ANTIBIOTICS INHIBITED THEREBY 审中-公开使用LYSIN恢复/接受抗生素抑制剂的脉冲表面活性剂的抗体活性
公开(公告)号：WO2017049242A2
公开(公告)日：2017-03-23
申请号：PCT/US2016/052348
申请日：2016-09-16
Applicant: CONTRAFECT CORPORATION
Inventor： WITTEKIND, Michael , SCHUCH, Raymond
IPC: A61K38/16 , A61K38/46 , A61K38/12 , A61K31/7036 , A61P31/04
CPC classification number: A61K38/46 , A61K31/7036 , A61K38/12 , A61K38/162 , A61K45/06 , Y02A50/473 , Y02A50/481 , A61K2300/00
Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.
Abstract translation: 本公开涉及在存在肺表面活性剂的器官或组织中恢复或增强抗生素的杀菌活性的方法。 更具体地，本公开内容描述了由于诸如呼吸上皮等器官或组织中的肺表面活性剂的环境因素引起的抗生素的抑制可以被回避或克服，并且该环境中抗生素的有效性恢复或增强 通过共同施用抗生素和溶素。
-
99.发明申请PHARMACEUTICAL ASSOCIATION OF GROWTH FACTOR RECEPTOR AGONIST AND ADHESION PROTEIN INHIBITOR FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF 审中-公开生长因子受体激动剂和粘附蛋白抑制剂的药代动力学协会，用于将神经细胞转化为非神经细胞及其用途
公开(公告)号：WO2017046229A1
公开(公告)日：2017-03-23
申请号：PCT/EP2016/071797
申请日：2016-09-15
Applicant: HISTIDE AG
Inventor： ZOUANI, Omar F. , GOCHEVA, Veronika
IPC: A61K38/05 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/16 , A61K39/395 , A61K45/06 , A61K31/70 , C07K16/28 , A61P35/00 , A61K38/18 , G06F19/16
CPC classification number: A61K38/05 , A61K31/7105 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/16 , A61K38/18 , A61K39/3955 , A61K45/06 , C07K16/2839 , C07K16/2854 , A61K2300/00
Abstract: A pharmaceutical association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one adhesion protein inhibitor which inhibits at least one transmembrane cell adhesion protein of said neoplastic cell.
Abstract translation: 一种药物结合物，其包含至少一种激活肿瘤细胞的至少一种生长因子受体的生长因子受体结合化合物和至少一种抑制所述肿瘤细胞的至少一种跨膜细胞粘附蛋白的粘附蛋白抑制剂。
-
100.发明申请PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF 审中-公开将肿瘤细胞转化为非肿瘤细胞的药物协会及其应用
公开(公告)号：WO2017046219A2
公开(公告)日：2017-03-23
申请号：PCT/EP2016/071785
申请日：2016-09-15
Applicant: HISTIDE AG
Inventor： ZOUANI, Omar F. , GOCHEVA, Veronika
IPC: A61K38/05 , A61L27/12 , A61L27/34 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , A61L27/54 , A61K38/18 , A61K9/16 , G06F19/16
CPC classification number: A61K38/18 , A61K38/05 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/12 , G06F19/16
Abstract: The present disclosure provides a pharmaceutical association for use in the treatment, prevention and/or diagnostic of a neoplastic disease, said association comprising at least one growth factor receptor-binding compound, which activates at least one growth factor receptor of a neoplastic cell, and at least one bioactive carrier forming at least one covalent or non-covalent interaction with said at least one growth factor receptor-binding compound, and wherein said association reduces or suppresses, in the neoplastic cell, the gene expression of at least one cyclin D and/or reduces or suppresses the formation of at least one complex formed between said at least one cyclin D and at least one of cyclin dependent-kinase 4 or 6.
Abstract translation: 本公开内容提供了用于治疗，预防和/或诊断赘生性疾病的药物协会，所述协会包含至少一种生长因子受体结合化合物，其激活至少一种生长 赘生性细胞的多因子受体和至少一种生物活性载体，其与所述至少一种生长因子受体结合化合物形成至少一种共价或非共价相互作用，并且其中所述缔合减少或抑制赘生性细胞中的基因 至少一种细胞周期蛋白D的表达和/或减少或抑制所述至少一种细胞周期蛋白D与细胞周期蛋白依赖性激酶4或6中的至少一种之间形成的至少一种复合物的形成。
-
-
-
-
-
-
-
-
-
Search Results
1628
records
(took 0.029 seconds)
